Oncology Failure Atlas
Request Access

Oncology Failure Atlas

Explore 11,525 terminated and withdrawn oncology trials through mapped discontinuation patterns, harmonized mechanisms, public evidence availability, and human-reviewable research context.

11,525 discontinued trialsPublic-source evidenceResearch navigation only
Explore AI Research Hub View methodology

Public data only · Source-linked evidence · RecurSignal™ is not predictive · No clinical or investment advice

How to use this platform

1

Filter the atlas

Start with an indication, mechanism, sponsor, phase, year, or discontinuation pattern.

2

Review public evidence context

Check source availability from ClinicalTrials.gov-derived records, AACT, PubMed, OpenFDA, CrossRef, and EMA context where available.

3

Export or generate a brief

Download the filtered evidence pack or generate an AI-assisted research brief for human review.

Looking for a specific concept? Open Trials Like Mine to compare against similar discontinued cohorts.

Start exploring the atlas

Filters update the dashboard, evidence coverage, recent examples, exports, and AI brief scope.

Current scope: loading dataset scope…

Dataset extracted from ClinicalTrials.gov · Terminated and withdrawn oncology trials · 2011–2024. Counts refer to different dataset layers. The full OFA dataset contains discontinued/withdrawn trial records; MDIP-mapped records reflect records with available discontinuation-pattern classification context.

Public Evidence Coverage

Availability signals from public sources. Missing evidence does not prove absence.

How OFA maps discontinuation patterns

MDIP™ maps public stop-reason language into comparable discontinuation-pattern categories.

Not mechanismNot predictionNot root-cause proof
View full MDIP methodology

When discontinued oncology trials were reported

Terminated and withdrawn oncology trials registered 2011–2024

Why trials were reported as stopped

Primary MDIP discontinuation-pattern category across records with mapped stop-reason context.

How recurrent these public discontinuation patterns appear historically

RecurSignal™ summary across classified records

Where discontinuation patterns cluster by phase

Darker cells indicate higher record volume for the selected discontinuation pattern and trial phase in the current filtered scope.

Recent discontinued-trial examples

Representative records from the current filtered scope. Use exports or Signal Explorer for deeper review.

Export Pack

Export scope: Full dataset · 0 records

Approved users can download CSV, XLSX, and PDF from the Downloads page.

AI Research Hub

NEWClaude-assisted, evidence-bound research drafting

OFA Research Brief Generator — turn the current OFA-filtered evidence pack into a human-reviewable core research brief.

Learn how this works
Pattern Summary
Oncology Failure Atlas maps public discontinuation-pattern context across 11,525 terminated and withdrawn oncology trials using source-linked public evidence. It is for research navigation only.
Public records show recruitment-related discontinuations in Phase 2 immuno-oncology trials within the current scope.
Hypothesis Generation
Generate research hypotheses from recurring mechanism and indication patterns.
Eligibility criteria and biomarker uncertainty may be limiting enrollment.
Literature & Gap Analysis
Surface linked literature and underexplored evidence gaps.
Limited studies on how biomarker thresholds affect enrollment in this population.
Research Questions
Translate historical patterns into testable research questions.
Which inclusion criteria correlate with lower enrollment?
Validation Plan
Draft a human-reviewable validation plan with data and confounders.
Retrospective review of similar trials and external datasets.
Explore AI Research Hub